Eligard — Medica
Head and neck cancer – salivary gland tumors
Initial criteria
- Patient has recurrent, unresectable, or metastatic disease.
- Patient has androgen receptor-positive disease.
- Medication is prescribed by or in consultation with an oncologist.
Approval duration
1 year